Design, Synthesis and Antitumor Activity of Novel link-bridge and B-Ring Modified Combretastatin A-4 (CA-4) Analogues as Potent Antitubulin Agents.

Sci Rep 2016 05 3;6:25387. Epub 2016 May 3.

State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, 163 Xianlin Road, P. R. China.

A series of 12 novel acylhydrazone, chalcone and amide-bridged analogues of combretastatin A-4 were designed and synthesized toward tubulin. All these compounds were determined by elemental analysis, (1)H NMR, and MS. Among them, compound 7 with acylhydrazone-bridge, bearing a benzyl at the indole-N position, was identified as a potent antiproliferative agent against a panel of cancer cell lines with IC50 values ranging from 0.08 to 35.6 μM. In contrast, its cytotoxic effects on three normal human cells were minimal. Cellular studies have revealed that the induction of apoptosis by compound 7 was associated with a collapse of mitochondrial membrane potential, accumulation of reactive oxygen species, alterations in the expression of some cell cycle-related proteins (Cyclin B1, Cdc25c, Cdc2, P21) and some apoptosis-related proteins (Bax, PARP, Bcl-2, Caspase3). The docking mode showed the binding posture of CA-4 and compound 7 are similar in the colchicine-binding pocket of tubulin, as confirmed by colchicine-tubulin competitive binding assay, tubulin polymerization inhibitory activity, extracellular protein expression determination assay and confocal immunofluorescence microscopy. In vivo study, compound 7 effectively inhibited A549 xenograft tumor growth without causing significant loss of body weight suggesting that compound 7 is a promising new antimitotic agent with clinical potential.

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep25387DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853715PMC
May 2016
43 Reads

Publication Analysis

Top Keywords

combretastatin a-4
8
compound
5
proteins cyclin
4
cyclin cdc25c
4
cdc25c cdc2
4
cycle-related proteins
4
cell cycle-related
4
alterations expression
4
expression cell
4
oxygen species
4
species alterations
4
cdc2 p21
4
bcl-2 caspase3
4
caspase3 docking
4
docking mode
4
mode binding
4
parp bcl-2
4
bax parp
4
p21 apoptosis-related
4
apoptosis-related proteins
4

References

(Supplied by CrossRef)

GR Pettit et al.
Experientia 1989

YA Elnakady et al.
Biochemical pharmacology 2004

B Singh et al.
Drugs 1987

HM Robinson et al.
Biochemistry and Cell Biology 1991

J Griggs et al.
The lancet oncology 2001

BA Teicher et al.
Clinical Cancer Research 2008

H-Y Lin et al.
Biochemical pharmacology 2015

CM Lin et al.
Molecular pharmacology 1988

J Yan et al.
Biochemical pharmacology 2015

C Vilanova et al.
European journal of medicinal chemistry 2014

PC Carvalho et al.
Environmental toxicology and pharmacology 2015

Similar Publications